Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Builds Hematology Pipeline Beyond B-Cell Disease

Executive Summary

Roche is not content with replacing its aging Rituxan franchise in blood cancers. At ASCO, the company described its long-term plans to solidify Gazyva as the new CD20 backbone for non-Hodgkin lymphomas while using Venclexta and even newer candidates like targeted therapy idasanutlin to extend into new blood cancer indications – including the high-need acute myeloid leukemia space.

Advertisement

Related Content

Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel